REBEKAH CHEN: Open Payments
NPI 1003283672 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,430 in 194 payments from 25 companies in 2025. Trend: 2023 $2,774 · 2024 $4,198 · 2025 $5,430
Food & beverage: $5,239Education: $192
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $650 |
| Organon LLC | 25 | $568 |
| GENZYME CORPORATION | 13 | $561 |
| LEO Pharma Inc. | 14 | $475 |
| Janssen Biotech, Inc. | 23 | $468 |
| Incyte Corporation | 11 | $446 |
| ABBVIE INC. | 15 | $445 |
| Lilly USA, LLC | 10 | $294 |
| Regeneron Healthcare Solutions, Inc. | 10 | $270 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $258 |
Products named: DUPIXENT, TREMFYA, COSENTYX, OPZELURA, ADBRY, SKYRIZI, VTAMA, TALTZ.
Industry payments across MD — which companies pay providers there.
